FYERS
Home
/
Stocks
/
Results
/
Anlon Healthcare Results

Anlon Healthcare Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---43%
---42%
---70%
22%22%22%19%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
AHCL
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,905.9₹456833 Cr37.7712.0762.82₹11479 Cr
9,210₹245426 Cr83.9134.04128.41₹2568 Cr
4,889.5₹187320 Cr85.8916.7297.06₹2163 Cr
1,133.5₹113217 Cr25.099.4262.53₹5040 Cr
1,390.6₹112212 Cr33.299.7757.87₹3879 Cr
1,853.3₹101155 Cr92.526.829.25₹889 Cr
2,124.1₹97626 Cr17.6630.95154.36₹5333 Cr
2,347.9₹96859 Cr47.4213.7571.08₹1913 Cr
1,164₹96406 Cr29.925.3263.99₹4196 Cr
1,656₹93614 Cr25.2217.9596.84₹3505 Cr
15.72₹829 Cr29.080.130.57₹29 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Jun 2025Mar 2025
₹88 Cr₹51 Cr₹33 Cr₹49 Cr
₹6 L₹1 L₹1 L₹4 L
₹88 Cr₹51 Cr₹33 Cr₹49 Cr
₹73 Cr₹36 Cr₹27 Cr₹33 Cr
₹16 Cr₹15 Cr₹6 Cr₹17 Cr
₹93 L₹57 L₹82 L₹91 L
₹14 Cr₹14 Cr₹5 Cr₹15 Cr
₹8 Cr₹11 Cr₹4 Cr₹17 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025
——
₹53 Cr₹40 Cr
₹177 Cr₹41 Cr
₹177 Cr₹41 Cr
₹230 Cr₹80 Cr
₹25 Cr₹0
₹6 Cr₹5 Cr
₹4 L₹34 Cr
₹5 Cr₹2 Cr
₹37 L₹24 L
₹12 Cr₹41 Cr
——
₹42 Cr₹20 Cr
₹14 Cr₹4 Cr
₹38 Cr₹28 Cr
₹14 Cr₹8 Cr
₹108 Cr₹60 Cr
₹374 Cr₹181 Cr
₹25 L₹0
₹44 Cr₹67 Cr
——
₹84 Cr₹36 Cr
₹26 Cr₹13 Cr
₹58 Cr₹23 Cr
₹98 L₹0
₹98 L₹0
₹7 Cr₹0
₹66 Cr₹23 Cr
——
₹1 L₹91 L
₹113 Cr₹50 Cr
₹104 Cr₹75 Cr
₹4 Cr₹1 Cr
₹1 Cr₹1 Cr
₹86 Cr₹30 Cr
₹308 Cr₹158 Cr
₹201 Cr₹98 Cr
₹374 Cr₹181 Cr
₹43₹20
₹4₹2

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025
₹43 Cr₹27 Cr
₹5 Cr-₹56 L
-₹122 Cr-₹54 Cr
-₹75 Cr-₹28 Cr
-₹79 Cr-₹23 Cr
-₹36 Cr₹3 Cr
₹119 Cr₹19 Cr
₹3 Cr-₹82 L
₹1 Cr₹2 Cr
₹4 Cr₹1 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)15.68
Volume (₹)11.52 L
High (₹)15.89
Upper Circuit18.72
Low (₹)15.63
Lower Circuit12.48
Prev Close15.60
52W High (₹)17.28
Price15.72
52W Low (₹)9.10

Share Market Cap & Key Ratios Overview

M.Cap (₹)829.16 Cr
Div. Yield (%)0.00
PE Ratio29.08
Debt to Equity0.19
Price to Book2.57
Book Value4.33
EPS (TTM)0.54
Face Value2.00
ROE (%)18.73

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
AHCLNSE
LTP
1W Low
1W High
Market cap (₹)
1903.7-16.3 (-0.85%)
1902
1984.80
4,56,833Cr
9182-57 (-0.62%)
9087
9467
2,45,426Cr
4902-148 (-2.93%)
4886.50
5066
1,87,320Cr
1134.9-56.1 (-4.71%)
1125.10
1187
1,13,217Cr
1392-31.5 (-2.21%)
1376.70
1426.10
1,12,212Cr
1853-85.5 (-4.41%)
1811.70
1949
1,01,155Cr
2124-47.5 (-2.19%)
2118.10
2192
97,626Cr
2351.8-31.1 (-1.31%)
2341.20
2419.20
96,859Cr
1164.8-13.2 (-1.12%)
1154.40
1179.90
96,406Cr
1652.2+6.9 (0.42%)
1622.60
1717
93,614Cr
15.72-0.19 (-1.19%)
15.32
16.25
829Cr

Anlon Healthcare Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹15.65Cr; with other income of ₹6Lakh, profit before interest and tax came to ₹14.58Cr. Interest expense was ₹92.5Lakh; PBT before exceptional items stood at ₹13.66Cr. Cost mix (full year): raw materials ₹149.31Cr; employee cost ₹5.54Cr; depreciation ₹1.07Cr; other expenses ₹71.97Cr. Basis: consolidated annual results.

Anlon Healthcare Ltd Quaterly Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹15.65Cr; with other income of ₹6Lakh, profit before interest and tax came to ₹14.58Cr. Interest expense was ₹92.5Lakh, taking profit before tax to ₹13.66Cr.